Dementia - what can Public Health do to respond to the scope for Prevention? - Olga Cleary
IPH, Open, Conference, Belfast, Northern, Ireland, Dublin, Titanic, October, 2014, Public, Health
This document summarizes information about epilepsy and seizures. It defines epilepsy as recurrent seizures and describes different types of seizures including focal-onset, generalized-onset, tonic-clonic, absence, myoclonic, atonic, and tonic seizures. Causes, pathophysiology, diagnosis and treatment options are discussed. Treatment involves antiepileptic medications as first-line treatment, with surgery, neurostimulation or dietary therapies as options for refractory cases. Potential risks and complications of treatments are also summarized.
This document discusses autoimmune encephalitis, which occurs due to antibodies against neuronal cell proteins or synaptic receptors. It can comprise 5-10% of encephalitis cases. The most common type is anti-NMDAR encephalitis, which targets the NMDA receptor. It most often affects females under 18 and follows a predictable clinical course with psychiatric, neurological, and decreased consciousness symptoms. Diagnosis involves identifying antibodies in CSF or serum and MRI/EEG may show nonspecific abnormalities. Treatment involves immunotherapy like steroids, IVIG, plasma exchange, and rituximab. Outcomes range from full recovery to relapse or residual deficits.
Narcolepsy is a condition characterized by excessive daytime sleepiness and symptoms that represent intrusion of REM sleep into waking hours. It is caused by a deficiency of the neurotransmitter hypocretin and is associated with HLA DQB1*0602. Symptoms include irresistible sleep attacks, cataplexy, sleep paralysis, and hypnagogic hallucinations. Diagnosis involves evaluating symptoms, sleep latency on polysomnography and multiple sleep latency tests, and hypocretin levels in cerebrospinal fluid. Treatment focuses on managing symptoms with stimulants like modafinil and antidepressants or SSRIs to reduce cataplexy.
Newer antiepileptic drugs (AEDs) such as eslicarbazepine, vigabatrin, lacosamide, clobazam, levetiracetam, lamotrigine, topiramate, zonisamide, oxcarbazepine have been introduced as adjunctive therapies for refractory epilepsy. These newer AEDs have fewer drug interactions and side effects than older AEDs. They target specific epilepsy syndromes in children. However, most are only used as adjunctive rather than monotherapy due to a lack of superiority trials compared to conventional AEDs. Dosing and use of the newer AEDs varies based on age, renal function
Levetiracetam is a broad-spectrum newer antiepileptic drug approved in 1999. It has fewer drug interactions than older AEDs due to simpler pharmacokinetics without enzyme induction. Its unique mechanism of action involves synaptic vesicle protein SV2A. Common adverse effects are mild and reversible. Lacosamide approved in 2008 is indicated as adjunctive therapy for focal seizures. It is initiated at 50mg twice daily and increased weekly by 100mg with a maximum of 400mg daily due to potential CNS and gastrointestinal side effects.
Autoimmune encephalitis current conceptsNeurologyKota
1) Autoimmune encephalitis is a debilitating neurological disorder caused by inflammation of the brain. It develops subacutely over weeks and can affect individuals of all ages.
2) It has diverse clinical manifestations and immunological associations. Identification of neural autoantibodies has led to classification of different subtypes.
3) Prominent among these are anti-NMDAR encephalitis commonly seen in young women and children, autoimmune limbic encephalitis, and other syndromes associated with antibodies targeting neuronal cell-surface and intracellular antigens.
Neuropsychiatric manifestations of systematic lupusdiscoverccs-org
Systemic lupus erythematosus (SLE) is an autoimmune disorder that causes inflammation and damage to multiple organs through the immune system attacking its own cells and tissues. Neuropsychiatric manifestations are common in SLE patients and can include headaches, seizures, mood disorders like depression and anxiety, and even rare symptoms like psychosis. The mechanisms are not fully understood but may involve changes to small blood vessels in the brain. Treatment options include corticosteroids, antimalarial drugs, antidepressants, and antipsychotics depending on symptoms.
This document discusses different types of autoimmune encephalitis. It categorizes autoimmune encephalitis as either paraneoplastic, non-paraneoplastic, or associated with vasculitis. Within non-paraneoplastic autoimmune encephalitis, several specific types are described that are associated with antibodies against receptors like NMDA, GABA, AMPA, and LGI1. Clinical features, pathogenesis, diagnosis and treatment approaches are summarized for some of the major types like anti-NMDA receptor encephalitis. Long term management involves immunosuppression with steroids and other agents to prevent relapse, though neurologic sequelae may still occur in some patients.
This document summarizes information about epilepsy and seizures. It defines epilepsy as recurrent seizures and describes different types of seizures including focal-onset, generalized-onset, tonic-clonic, absence, myoclonic, atonic, and tonic seizures. Causes, pathophysiology, diagnosis and treatment options are discussed. Treatment involves antiepileptic medications as first-line treatment, with surgery, neurostimulation or dietary therapies as options for refractory cases. Potential risks and complications of treatments are also summarized.
This document discusses autoimmune encephalitis, which occurs due to antibodies against neuronal cell proteins or synaptic receptors. It can comprise 5-10% of encephalitis cases. The most common type is anti-NMDAR encephalitis, which targets the NMDA receptor. It most often affects females under 18 and follows a predictable clinical course with psychiatric, neurological, and decreased consciousness symptoms. Diagnosis involves identifying antibodies in CSF or serum and MRI/EEG may show nonspecific abnormalities. Treatment involves immunotherapy like steroids, IVIG, plasma exchange, and rituximab. Outcomes range from full recovery to relapse or residual deficits.
Narcolepsy is a condition characterized by excessive daytime sleepiness and symptoms that represent intrusion of REM sleep into waking hours. It is caused by a deficiency of the neurotransmitter hypocretin and is associated with HLA DQB1*0602. Symptoms include irresistible sleep attacks, cataplexy, sleep paralysis, and hypnagogic hallucinations. Diagnosis involves evaluating symptoms, sleep latency on polysomnography and multiple sleep latency tests, and hypocretin levels in cerebrospinal fluid. Treatment focuses on managing symptoms with stimulants like modafinil and antidepressants or SSRIs to reduce cataplexy.
Newer antiepileptic drugs (AEDs) such as eslicarbazepine, vigabatrin, lacosamide, clobazam, levetiracetam, lamotrigine, topiramate, zonisamide, oxcarbazepine have been introduced as adjunctive therapies for refractory epilepsy. These newer AEDs have fewer drug interactions and side effects than older AEDs. They target specific epilepsy syndromes in children. However, most are only used as adjunctive rather than monotherapy due to a lack of superiority trials compared to conventional AEDs. Dosing and use of the newer AEDs varies based on age, renal function
Levetiracetam is a broad-spectrum newer antiepileptic drug approved in 1999. It has fewer drug interactions than older AEDs due to simpler pharmacokinetics without enzyme induction. Its unique mechanism of action involves synaptic vesicle protein SV2A. Common adverse effects are mild and reversible. Lacosamide approved in 2008 is indicated as adjunctive therapy for focal seizures. It is initiated at 50mg twice daily and increased weekly by 100mg with a maximum of 400mg daily due to potential CNS and gastrointestinal side effects.
Autoimmune encephalitis current conceptsNeurologyKota
1) Autoimmune encephalitis is a debilitating neurological disorder caused by inflammation of the brain. It develops subacutely over weeks and can affect individuals of all ages.
2) It has diverse clinical manifestations and immunological associations. Identification of neural autoantibodies has led to classification of different subtypes.
3) Prominent among these are anti-NMDAR encephalitis commonly seen in young women and children, autoimmune limbic encephalitis, and other syndromes associated with antibodies targeting neuronal cell-surface and intracellular antigens.
Neuropsychiatric manifestations of systematic lupusdiscoverccs-org
Systemic lupus erythematosus (SLE) is an autoimmune disorder that causes inflammation and damage to multiple organs through the immune system attacking its own cells and tissues. Neuropsychiatric manifestations are common in SLE patients and can include headaches, seizures, mood disorders like depression and anxiety, and even rare symptoms like psychosis. The mechanisms are not fully understood but may involve changes to small blood vessels in the brain. Treatment options include corticosteroids, antimalarial drugs, antidepressants, and antipsychotics depending on symptoms.
This document discusses different types of autoimmune encephalitis. It categorizes autoimmune encephalitis as either paraneoplastic, non-paraneoplastic, or associated with vasculitis. Within non-paraneoplastic autoimmune encephalitis, several specific types are described that are associated with antibodies against receptors like NMDA, GABA, AMPA, and LGI1. Clinical features, pathogenesis, diagnosis and treatment approaches are summarized for some of the major types like anti-NMDA receptor encephalitis. Long term management involves immunosuppression with steroids and other agents to prevent relapse, though neurologic sequelae may still occur in some patients.
The document discusses progressive myoclonus epilepsy (PME), which consists of myoclonic seizures, tonic-clonic seizures, and progressive neurological dysfunction like ataxia and dementia. The main causes of PME include Unverricht-Lundborg disease, myoclonic epilepsy with ragged-red fiber syndrome, Lafora body disease, neuronal ceroid lipofuscinoses, and sialidoses. Lafora body disease is characterized by myoclonus, seizures, ataxia, dementia and inclusion bodies. It has autosomal recessive inheritance and death usually occurs within 10 years of onset. Management involves treatment of seizures and myoclonus with medications like
The document discusses drug resistant epilepsy, providing an overview of pathophysiology, clinical aspects, and management. It notes that approximately 30% of epilepsy patients have drug resistant epilepsy where seizures persist despite trials of two or more antiepileptic drugs. For these patients, resective epilepsy surgery has significantly higher chances of seizure freedom compared to further medication trials. A comprehensive presurgical evaluation is required to identify the epileptogenic zone and determine surgical candidacy and risks. The evaluation involves extensive diagnostic testing including long-term video EEG monitoring, neuroimaging, neuropsychological testing, and in some cases intracranial monitoring.
1) Cognitive decline is a normal part of aging, but dementia is characterized by multiple cognitive deficits severe enough to interfere with daily life. The DSM-V criteria distinguish between mild and major neurocognitive disorders.
2) Mild cognitive impairment (MCI) represents an intermediate stage between normal aging and dementia, with greater cognitive decline than normal but preserved independence. Amnestic MCI is highly predictive of Alzheimer's disease.
3) Biomarkers like MRI, CSF analysis, PET imaging, and genetics can help predict conversion from MCI to dementia and distinguish Alzheimer's disease from other causes. Biomarkers show changes decades before symptoms appear in preclinical Alzheimer's disease.
Module: Pharmacotherapy III
Module Coordinator: Dr. Arwa M. Amin Mostafa
Academic Level: Postgraduate, Master of Pharmacy in Clinical Pharmacy
School: Dubai Pharmacy College
Year of first presented in Class: 2018
This presentation is for Educational purpose. It has no commercial value associated with it.
This document discusses treatment resistant depression. It begins by providing epidemiological data on depression worldwide and notes that treatment resistant depression (TRD) is becoming more prevalent. It then discusses factors associated with TRD like psychiatric and medical comorbidities, gender, family history, illness severity and chronicity. The document outlines approaches to defining and staging TRD. It discusses challenges in differentiating true treatment resistance from pseudo-resistance. Finally, it summarizes large clinical trials on sequencing treatments for TRD like the STAR*D trial.
The document discusses recent advances in the treatment of epilepsy. It describes several new antiepileptic drugs that have been approved by the FDA in recent years, including clobazam, eslicarbazepine, ezogabine, lacosamide, perampanel, and topiramate extended release. These new drugs act through mechanisms such as enhancing GABAergic transmission, blocking sodium channels, and antagonizing glutamate receptors. The document also discusses the need for improved treatments given the limitations of current options and the fact that around one third of epilepsy patients have drug-resistant seizures.
Transient global amnesia (TGA) is a temporary loss of memory that resolves within 24 hours. It typically affects people ages 40-80 and has an unknown cause, but may involve temporary reduced blood flow in the hippocampus. TGA is characterized by the acute onset of anterograde amnesia without other neurological deficits. Evaluation aims to rule out other conditions, and most patients fully recover without treatment within hours.
Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect the central nervous system and cause neuropsychiatric symptoms. Diagnosing neuropsychiatric SLE (NPSLE) is challenging due to its diverse manifestations. Genetic, autoantibody, and cytokine factors may contribute to NPSLE pathogenesis by disrupting the blood-brain barrier and causing inflammatory changes. Treatment involves immunosuppression but outcomes depend on the specific neuropsychiatric symptoms.
Dementia can sometimes be caused by reversible conditions. This document discusses several potential reversible causes of dementia, including thyroid disorders, vitamin deficiencies, infections, and side effects of medications like steroids. It provides details on specific disorders and how treatment of the underlying condition may resolve cognitive and behavioral symptoms. Reversible dementias are estimated to account for 18% of cases under 65 but only 5% of those over 65. While treatment can sometimes improve symptoms, complete reversion of cognitive impairment is unclear for certain conditions like Cushing's syndrome.
This document discusses several types of autoimmune encephalitis, including Hashimoto's encephalopathy, NMDA encephalitis, and limbic encephalitis. Hashimoto's encephalopathy is defined by the presence of thyroid peroxidase antibodies in patients with encephalitis that responds to steroids. It can cause non-specific neurological symptoms. NMDA encephalitis commonly affects young women and can cause psychiatric issues, decreased consciousness, and movement disorders. Diagnosis involves detecting NMDA receptor antibodies in CSF or serum. Limbic encephalitis involves inflammation of limbic structures and is associated with antibodies against proteins like LGI1; it typically causes memory loss, behavioral changes and seizures in older patients.
This document discusses various types of autoimmune encephalitis. It begins by providing clues that can suggest an autoimmune cause over infectious, including a subacute onset and fluctuating course. It then covers several specific autoimmune encephalitis subtypes defined by the neuronal surface antigens involved, such as anti-NMDA receptor and anti-LGI1 encephalitis. For each subtype, it discusses clinical features, investigations, and treatment approaches. The document aims to help clinicians differentiate between autoimmune and infectious causes of encephalitis.
This document discusses epilepsy management in patients with comorbid systemic disorders. It focuses on how liver disease, kidney disease, porphyria, infections, brain tumors, and strokes can impact epilepsy treatment. For liver disease, levetiracetam, lacosamide, topiramate, gabapentin and pregabalin are recommended first-line therapies due to their limited hepatic metabolism and excretion. For kidney disease, drug dosages may need adjustment based on creatinine clearance levels. Non-enzyme inducing antiepileptic drugs are preferred for patients with porphyria or infections. Levetiracetam has shown efficacy for brain tumor-related seizures while minimizing interactions with cancer treatments. Interactions with other medications
This document discusses autoimmune encephalitis, which is caused by antibodies targeting neuronal cell surface or synaptic antigens. It can present with various neuropsychiatric symptoms and be misdiagnosed as viral encephalitis. Diagnosis is confirmed by detecting antibodies in CSF and serum, often against NMDA receptors. Treatment involves immunotherapy like steroids, IVIg, or plasma exchange. Outcomes are generally good if treated promptly, though some disorders relapse. Tumor removal may also be needed if one is present.
This document provides information on epileptic encephalopathies that onset in infancy, including definitions and classifications. It describes several specific syndromes - Early Myoclonic Encephalopathy (EME), Ohtahara syndrome, West syndrome, and Dravet syndrome. EME is characterized by erratic myoclonus, focal seizures, and spasms in the first weeks of life, along with a burst suppression pattern on EEG. Ohtahara syndrome involves tonic spasms in the first months with a continuous burst suppression EEG. West syndrome consists of epileptic spasms, developmental delay/regression, and a hypsarrhythmic EEG. Dravet syndrome begins with prolonged febrile
This case summary describes a 4-year-old male child who presented with cough, cold, fever, and seizure followed by altered sensorium for 15 days prior to admission. He had been hospitalized for 15 days at a private hospital where he was on mechanical ventilation for 10 days and received a tracheostomy tube. Testing showed normal CBC, SE, CSF study, viral markers, CSF NMDA receptor study, and MRI. He received multiple antiepileptics and steroids with some improvement in condition but remained dependent on the tracheostomy tube. The summary discusses various types and causes of encephalitis including autoimmune encephalitis such as anti-NMDA receptor encephalitis, LGI1 encephalitis
This is a brief review of autoimmune epilepsies, especially autoimmune encephalitis, SREAT, NORSE, FIRES and Rasmussen's encephalitis. A brief overview of investigations and treatment is included.
This document summarizes research on the course and outcome of schizophrenia. It discusses several landmark studies including the International Pilot Study of Schizophrenia, Determinants of Outcome of Severe Mental Disorder study, and International Study of Schizophrenia. Overall, the studies found that outcomes tended to be better in developing countries compared to developed countries. Within developing countries, outcomes were particularly good in India, with studies in Agra and Chandigarh finding high rates of remission. Acute onset, good premorbid adjustment, younger age, and shorter duration of initial psychotic episode predicted better long-term prognosis.
Ad webinar diet and exercise to prevent cognitive declinewef
The document provides information about a webinar on Alzheimer's disease and dementia prevention. It discusses proper webinar etiquette, introduces the panelists and moderator, and outlines topics including the most common forms of dementia, risk factors, protective strategies like physical activity and nutrition, latest research findings, and tips for healthy brain aging.
This document discusses ways to prevent Alzheimer's disease through 2050. It suggests that antioxidants and omega-3 fatty acids like DHA may help reduce free radicals and decrease the risk of dementia. The document calls for further research and action to address the growing problem of Alzheimer's as the population ages.
The document discusses progressive myoclonus epilepsy (PME), which consists of myoclonic seizures, tonic-clonic seizures, and progressive neurological dysfunction like ataxia and dementia. The main causes of PME include Unverricht-Lundborg disease, myoclonic epilepsy with ragged-red fiber syndrome, Lafora body disease, neuronal ceroid lipofuscinoses, and sialidoses. Lafora body disease is characterized by myoclonus, seizures, ataxia, dementia and inclusion bodies. It has autosomal recessive inheritance and death usually occurs within 10 years of onset. Management involves treatment of seizures and myoclonus with medications like
The document discusses drug resistant epilepsy, providing an overview of pathophysiology, clinical aspects, and management. It notes that approximately 30% of epilepsy patients have drug resistant epilepsy where seizures persist despite trials of two or more antiepileptic drugs. For these patients, resective epilepsy surgery has significantly higher chances of seizure freedom compared to further medication trials. A comprehensive presurgical evaluation is required to identify the epileptogenic zone and determine surgical candidacy and risks. The evaluation involves extensive diagnostic testing including long-term video EEG monitoring, neuroimaging, neuropsychological testing, and in some cases intracranial monitoring.
1) Cognitive decline is a normal part of aging, but dementia is characterized by multiple cognitive deficits severe enough to interfere with daily life. The DSM-V criteria distinguish between mild and major neurocognitive disorders.
2) Mild cognitive impairment (MCI) represents an intermediate stage between normal aging and dementia, with greater cognitive decline than normal but preserved independence. Amnestic MCI is highly predictive of Alzheimer's disease.
3) Biomarkers like MRI, CSF analysis, PET imaging, and genetics can help predict conversion from MCI to dementia and distinguish Alzheimer's disease from other causes. Biomarkers show changes decades before symptoms appear in preclinical Alzheimer's disease.
Module: Pharmacotherapy III
Module Coordinator: Dr. Arwa M. Amin Mostafa
Academic Level: Postgraduate, Master of Pharmacy in Clinical Pharmacy
School: Dubai Pharmacy College
Year of first presented in Class: 2018
This presentation is for Educational purpose. It has no commercial value associated with it.
This document discusses treatment resistant depression. It begins by providing epidemiological data on depression worldwide and notes that treatment resistant depression (TRD) is becoming more prevalent. It then discusses factors associated with TRD like psychiatric and medical comorbidities, gender, family history, illness severity and chronicity. The document outlines approaches to defining and staging TRD. It discusses challenges in differentiating true treatment resistance from pseudo-resistance. Finally, it summarizes large clinical trials on sequencing treatments for TRD like the STAR*D trial.
The document discusses recent advances in the treatment of epilepsy. It describes several new antiepileptic drugs that have been approved by the FDA in recent years, including clobazam, eslicarbazepine, ezogabine, lacosamide, perampanel, and topiramate extended release. These new drugs act through mechanisms such as enhancing GABAergic transmission, blocking sodium channels, and antagonizing glutamate receptors. The document also discusses the need for improved treatments given the limitations of current options and the fact that around one third of epilepsy patients have drug-resistant seizures.
Transient global amnesia (TGA) is a temporary loss of memory that resolves within 24 hours. It typically affects people ages 40-80 and has an unknown cause, but may involve temporary reduced blood flow in the hippocampus. TGA is characterized by the acute onset of anterograde amnesia without other neurological deficits. Evaluation aims to rule out other conditions, and most patients fully recover without treatment within hours.
Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect the central nervous system and cause neuropsychiatric symptoms. Diagnosing neuropsychiatric SLE (NPSLE) is challenging due to its diverse manifestations. Genetic, autoantibody, and cytokine factors may contribute to NPSLE pathogenesis by disrupting the blood-brain barrier and causing inflammatory changes. Treatment involves immunosuppression but outcomes depend on the specific neuropsychiatric symptoms.
Dementia can sometimes be caused by reversible conditions. This document discusses several potential reversible causes of dementia, including thyroid disorders, vitamin deficiencies, infections, and side effects of medications like steroids. It provides details on specific disorders and how treatment of the underlying condition may resolve cognitive and behavioral symptoms. Reversible dementias are estimated to account for 18% of cases under 65 but only 5% of those over 65. While treatment can sometimes improve symptoms, complete reversion of cognitive impairment is unclear for certain conditions like Cushing's syndrome.
This document discusses several types of autoimmune encephalitis, including Hashimoto's encephalopathy, NMDA encephalitis, and limbic encephalitis. Hashimoto's encephalopathy is defined by the presence of thyroid peroxidase antibodies in patients with encephalitis that responds to steroids. It can cause non-specific neurological symptoms. NMDA encephalitis commonly affects young women and can cause psychiatric issues, decreased consciousness, and movement disorders. Diagnosis involves detecting NMDA receptor antibodies in CSF or serum. Limbic encephalitis involves inflammation of limbic structures and is associated with antibodies against proteins like LGI1; it typically causes memory loss, behavioral changes and seizures in older patients.
This document discusses various types of autoimmune encephalitis. It begins by providing clues that can suggest an autoimmune cause over infectious, including a subacute onset and fluctuating course. It then covers several specific autoimmune encephalitis subtypes defined by the neuronal surface antigens involved, such as anti-NMDA receptor and anti-LGI1 encephalitis. For each subtype, it discusses clinical features, investigations, and treatment approaches. The document aims to help clinicians differentiate between autoimmune and infectious causes of encephalitis.
This document discusses epilepsy management in patients with comorbid systemic disorders. It focuses on how liver disease, kidney disease, porphyria, infections, brain tumors, and strokes can impact epilepsy treatment. For liver disease, levetiracetam, lacosamide, topiramate, gabapentin and pregabalin are recommended first-line therapies due to their limited hepatic metabolism and excretion. For kidney disease, drug dosages may need adjustment based on creatinine clearance levels. Non-enzyme inducing antiepileptic drugs are preferred for patients with porphyria or infections. Levetiracetam has shown efficacy for brain tumor-related seizures while minimizing interactions with cancer treatments. Interactions with other medications
This document discusses autoimmune encephalitis, which is caused by antibodies targeting neuronal cell surface or synaptic antigens. It can present with various neuropsychiatric symptoms and be misdiagnosed as viral encephalitis. Diagnosis is confirmed by detecting antibodies in CSF and serum, often against NMDA receptors. Treatment involves immunotherapy like steroids, IVIg, or plasma exchange. Outcomes are generally good if treated promptly, though some disorders relapse. Tumor removal may also be needed if one is present.
This document provides information on epileptic encephalopathies that onset in infancy, including definitions and classifications. It describes several specific syndromes - Early Myoclonic Encephalopathy (EME), Ohtahara syndrome, West syndrome, and Dravet syndrome. EME is characterized by erratic myoclonus, focal seizures, and spasms in the first weeks of life, along with a burst suppression pattern on EEG. Ohtahara syndrome involves tonic spasms in the first months with a continuous burst suppression EEG. West syndrome consists of epileptic spasms, developmental delay/regression, and a hypsarrhythmic EEG. Dravet syndrome begins with prolonged febrile
This case summary describes a 4-year-old male child who presented with cough, cold, fever, and seizure followed by altered sensorium for 15 days prior to admission. He had been hospitalized for 15 days at a private hospital where he was on mechanical ventilation for 10 days and received a tracheostomy tube. Testing showed normal CBC, SE, CSF study, viral markers, CSF NMDA receptor study, and MRI. He received multiple antiepileptics and steroids with some improvement in condition but remained dependent on the tracheostomy tube. The summary discusses various types and causes of encephalitis including autoimmune encephalitis such as anti-NMDA receptor encephalitis, LGI1 encephalitis
This is a brief review of autoimmune epilepsies, especially autoimmune encephalitis, SREAT, NORSE, FIRES and Rasmussen's encephalitis. A brief overview of investigations and treatment is included.
This document summarizes research on the course and outcome of schizophrenia. It discusses several landmark studies including the International Pilot Study of Schizophrenia, Determinants of Outcome of Severe Mental Disorder study, and International Study of Schizophrenia. Overall, the studies found that outcomes tended to be better in developing countries compared to developed countries. Within developing countries, outcomes were particularly good in India, with studies in Agra and Chandigarh finding high rates of remission. Acute onset, good premorbid adjustment, younger age, and shorter duration of initial psychotic episode predicted better long-term prognosis.
Ad webinar diet and exercise to prevent cognitive declinewef
The document provides information about a webinar on Alzheimer's disease and dementia prevention. It discusses proper webinar etiquette, introduces the panelists and moderator, and outlines topics including the most common forms of dementia, risk factors, protective strategies like physical activity and nutrition, latest research findings, and tips for healthy brain aging.
This document discusses ways to prevent Alzheimer's disease through 2050. It suggests that antioxidants and omega-3 fatty acids like DHA may help reduce free radicals and decrease the risk of dementia. The document calls for further research and action to address the growing problem of Alzheimer's as the population ages.
Global Dementia Legacy Event: Raj Long, Senior Regulatory OfficerDepartment of Health
Raj Long presented on regulatory challenges for dementia treatment development and proposed innovative regulatory approaches. Key challenges included the prolonged time required for R&D, uncertainties around classifying and measuring dementia, and regulatory variances between geographies. These factors increase costs and risks for pharmaceutical companies, deterring investment. To address this, Long suggested regulatory designations to expedite review, adaptive development and licensing models, increased international regulator collaboration, incentives for developers, and public-private partnerships to accelerate cure discovery by 2025. Current approaches were deemed insufficient given the high risks and costs of dementia R&D.
The document discusses a workshop on public health and mental health. It provides background information on the voluntary sector's role in public health and improving health in Hertfordshire. Statistics are given on the prevalence of depression and dementia in the area. Projections show the elderly population and those with dementia will increase significantly by 2020. The workshop aims to discuss how the voluntary sector can contribute to public health services, policy development, and tackling health inequalities.
European Chiropractor's Union - 2014 - Dublinjpndresearch
Derick Mitchell, Communications Executive JPND, delivered a JPND presentation during the "A tidal wave of neurodegeneration is coming" session as part of the 2014 meeting of the European Chiropractor's Union
Movers & Shakers: Health and Wellbeing for Older PeopleUniversity of Bath
Presentation by Olga McBarnett for the ESRC Seminar Series on Ageing and Physical Activity - "Community based showcase: Building sustained partnerships and sharing resources"
http://seminars.ecehh.org
Global Dementia Legacy Event: Ms Inez Jabalpurwala, President and CEO, Brain ...Department of Health
Session Two: Barriers to investment in research to find a disease modifying therapy or cure for dementia
Ms Inez Jabalpurwala, President and CEO, Brain Canada Foundation
3 forette prevention of alzheimer ifa 2012] 2ifa2012
The document discusses potential approaches for preventing Alzheimer's disease and dementia. It notes that while some observational studies have found associations between certain factors and reduced dementia risk, large randomized controlled trials have not shown that anti-inflammatory agents, antioxidants, or estrogen therapy can prevent Alzheimer's disease. The document does provide evidence from randomized trials that treating hypertension through blood pressure lowering agents can reduce incidence of dementia. It summarizes trials showing reduced dementia risk when treating hypertension with calcium channel blockers, ACE inhibitors, and diuretics.
Improved lighting can help the UK’s ageing population enjoy their lives, improve their health and avoid some of distressing conditions of old age. Lighting solutions and technologies are often more cost-effective than drug-based treatments. You will see through this presentation how well-designed lighting can lead to improved health and alertness – and how we might push the issue up the health agenda.
Talk by Carl Gardner, CSG Lighting Consultancy Ltd
While Filipinos are living longer lives on average, chronic noncommunicable diseases now pose the greatest health challenges. Filipinos are increasingly getting sick and dying from heart disease, cancer, stroke, and other noncommunicable conditions. These diseases disproportionately affect the elderly population and prevalence increases with age. However, more males are affected by heart disease while breast cancer remains the leading cause of death among females. Lung cancer has the highest mortality rate among both sexes. The leading health risks result from combinations of aging, genetics, and lifestyle factors like smoking.
Dementia introduction slides by swapnakishore released cc-by-nc-saSwapna Kishore
Dementia awareness presentation intended for general public/ patients/ potential and existing caregivers/ volunteers interested in spreading dementia awareness.
Visit my site for more information: http://dementiacarenotes.in
Mitochondrial DNA (mtDNA) encodes proteins that are essential components of the oxidative phosphorylation (OXPHOS) system located in the inner mitochondrial membrane. Defects in mtDNA or nuclear genes involved in mitochondrial functions can cause a wide range of mitochondrial diseases. MtDNA is maternally inherited and mutations can be transmitted from mother to offspring. Common mitochondrial diseases include Chronic Progressive External Ophthalmoplegia (CPEO), Kearns-Sayre Syndrome (KSS), MELAS, MERRF, and Leber Hereditary Optic Neuropathy (LHON). These diseases have varying clinical features depending on the mutation and often affect the brain, muscles, and eyes.
The document discusses dementia, including that the development of dementia is increasing rapidly as the population ages. It notes that the individual chose to research dementia because it is becoming more common and they want to work in healthcare. The document then provides an overview of dementia that will be discussed in more detail, including causes, symptoms, diagnosis and treatment. It states that dementia is not one disease but a collection of symptoms caused by various disorders.
This document outlines a study on the prevalence and associated factors of diabetes mellitus among adults in Burao General Hospital, Somaliland in 2021. The study will use a cross-sectional design to collect data from 384 adult patients using systematic random sampling. Variables like age, marital status, education level and income will be assessed for their association with diabetes prevalence. Data will be collected using questionnaires and blood sugar testing, then analyzed using SPSS. Results will be disseminated to relevant health organizations to inform diabetes prevention and treatment.
This document discusses global efforts to address dementia and presents strategies for improving dementia care. It notes that most of the burden of dementia is in low and middle income countries and outlines a public health approach. This includes integrating dementia care into primary care, task-shifting to train non-specialists, and addressing barriers to access. It also reviews evidence for approaches like the WHO ICOPE model and discusses challenges in high-income countries like increasing diagnostic rates and controlling costs while maintaining quality. Overall it advocates for implementing evidence-based packages of dementia care globally using scalable, affordable, home-based models.
Συχνότερα χρόνια νοσήματα, καταστάσεις υγείας, συχνότερα συμπτώματα στην κοιν...Evangelos Fragkoulis
Σεμινάριο εισαγωγής στην ΠΦΥ- Εκπαιδευτικό πρόγραμμα ειδικευόμενων Γενικών Οικογενειακών Ιατρών σε συνεργασία με το Τμήμα Πολιτικών Δημόσιας Υγείας του Πανεπιστημίου Δυτικής Αττικής
Inequalities presentation SQAS Preston away day October 2018PHEScreening
This document summarizes discussions from a networking day on screening inequalities. It defines health inequalities and outlines Public Health England's (PHE) strategy to reduce inequalities in screening. The strategy aims to ensure all communities can access screening and make informed choices. It identifies groups most affected by screening inequalities, including those in deprived areas or from minority ethnic groups. The principle of proportionate universalism is discussed, where actions must be universal but more intensive for disadvantaged groups. Challenges in addressing screening inequalities are presented, and examples given of work done to improve access for people with serious mental illness.
Inequalities presentation preston away day october 2018PHEScreening
The document summarizes a meeting about health inequalities and the Public Health England (PHE) Screening Division's Inequalities Strategy. It discusses how screening inequalities can occur and groups most affected. The strategy aims to maximize health outcomes and reduce inequality burdens through leadership, evidence, and tools. It promotes proportionate universalism and collecting data on protected groups. Challenges include addressing inequalities at all screening stages. Examples focus on improving serious mental illness screening access. The strategy provides a mandate to address inequalities through awareness, local expertise, audit, and program board consideration.
Patricia Leahy Warren, Senior Lecturer School of Nursing and Midwifery, UCCInvestnet
The document summarizes the key challenges at the interface between primary and secondary healthcare in Ireland. It notes the changing demographic profiles of an aging population and increasing rates of chronic conditions. There are also challenges around communication and integration between primary care teams and specialist services due to incompatible IT systems and a lack of standardized documentation. The document calls for innovations to further develop integrated care centered around the needs of the individual and focused on preventative measures and community-based support over hospital-based care.
Vision health an integral part of public health in nigeriaChibuzor Emereole
A article on why vision care should be inclusive in the Nigerian concept of public health. The article provides the avenues through which advocacy, and public-private partnerships can be employed to achieve this feat, in view of the VISION 2020 - Right to Sight by all by the year 2020.
The document discusses the rationale and logistics for establishing a chronic kidney disease (CKD) clinic. It notes that CKD is a growing problem due to the rise of lifestyle diseases like diabetes and hypertension. A CKD clinic would take a multidisciplinary team approach to managing CKD patients and aim to slow disease progression, control comorbidities, and delay the need for renal replacement therapies. Studies show that CKD clinics that coordinate specialized care result in better health outcomes for patients than traditional nephrology care models.
OVEARVIEW OF NON-COMMUNICABLE DISEASES IN LEOTHO SEJOJO PHAAROE
Chronic non infectious diseases that are silent and persecute mankind . non-communicable disease (NCD) is a disease that is not transmissible directly from one person to another. NCDs include Parkinson's disease, autoimmune diseases, strokes, heart diseases, cancers, diabetes, chronic kidney disease, osteoarthritis, osteoporosis, Alzheimer's disease, cataracts, and other
Overview of tackling non-communicable diseases in EnglandDr Justin Varney
A presentation I gave in 2014 to a senior delegation of officials from Iraq on our approach in England to addressing the challenge of non-communicable disease
The document discusses diabetic retinopathy in India and globally. Some key points:
- Diabetic retinopathy is a leading cause of blindness and its prevalence is increasing worldwide, including in India which has a large diabetic population.
- India is projected to have the largest number of diabetics in the world by 2030, increasing the burden of diabetic retinopathy.
- Screening efforts and awareness of retinopathy need to be increased in India to detect and treat cases early.
- Managing risk factors like blood sugar, blood pressure, and lipids through coordinated care between eye doctors and diabetic doctors can help prevent vision loss from retinopathy.
Integrating technology into mental health and addiction treatment can help overcome barriers to access. E-health programs like SHADE and iTreAD provide online cognitive behavioral therapy to treat comorbid depression and substance use through modules addressing behaviors, thoughts, cravings and relapse prevention. While some populations may be wary of e-health due to concerns about trust, privacy and impersonal nature, studies found no differences in alliance, satisfaction or outcomes between online and in-person CBT. With proper promotion and transparency about program development, e-health can effectively expand treatment access for comorbid disorders.
Global mental health is a significant public health issue, with around 450 million people worldwide suffering from neuropsychiatric conditions. Depression is one of the leading causes of disability worldwide. Large international studies like the 10/66 study have helped measure the prevalence of mental disorders across different countries and cultures, finding that conditions like dementia and depression are highly prevalent and associated with substantial disability. However, there remain many barriers to improving mental health globally, including insufficient funding, stigma, and lack of trained healthcare workers. Advocacy is needed to promote human rights and reduce treatment gaps for mental disorders.
Measuring the patient’s perspective of the benefits of diabetes interventionsKeith Meadows
This document summarizes a webinar presented by Dr. Keith Meadows on measuring patient perspectives of diabetes interventions using the Diabetes Health Profile (DHP). The DHP is an outcome measure that assesses the psychological and behavioral impact of living with diabetes. It was developed based on patient interviews and focuses on domains like psychological distress, barriers to activity, and disinhibited eating. The DHP has been translated into many languages and can be used to evaluate treatment effectiveness and support programs from the patient's perspective.
The document discusses a program called PIPS (Program for Integrative Psychiatry) implemented at Psychiatric Hospital "Sveti Ivan" in Croatia to address high rates of physical illness and mortality in patients with serious mental illness like schizophrenia and bipolar disorder. PIPS is a 3-step program that includes comprehensive physical exams, screening for risk factors, personalized treatment, and lifestyle change programs. The goals are to reduce mortality, provide integrated physical and mental health care, encourage rehabilitation, and improve quality of life for psychiatric patients managing chronic medical conditions.
Prevention of mortality and morbidity in acute and chronic psychiatric patientsfilipcic555
This document outlines a program for integrative psychiatry (PIPS) developed at Psychiatric Hospital „Sveti Ivan” in Zagreb, Croatia to address the high rates of physical illness and mortality in patients with serious mental illness like schizophrenia and bipolar disorder. The PIPS program takes a three step approach: 1) preventative screening and monitoring of physical health indicators, 2) personalized psychiatric treatment and monitoring, and 3) lifestyle change programs. The goal is to improve detection of physical comorbidities and reduce mortality through a collaborative, multi-disciplinary approach integrating psychiatric and physical healthcare.
- The document discusses the relationship between nutrition, diet, and general and dental health. It explores topics like chronic health conditions linked to oral health, macronutrients and micronutrients that promote health, and providing nutritional guidance.
- Key points discussed include the role of fermentable carbohydrates in dental caries and periodontal diseases, common risk factors like sugar intake, and vitamin deficiencies. Data on conditions like heart disease, diabetes, and obesity in New Zealand are presented.
- Barriers to dental professionals providing dietary advice like time, knowledge, and confidence are examined based on past studies. The document advocates a holistic approach and collaborating with other health practitioners.
Anticholinergic Drugs And Risk Of Dementia Case-Control StudySandra Long
This study examined the association between use of anticholinergic drugs and risk of dementia using a nested case-control study of over 40,000 patients with dementia and nearly 284,000 controls without dementia in the UK. The study found that 35% of dementia cases compared to 30% of controls had been prescribed anticholinergic drugs with definite anticholinergic activity. Drugs with definite anticholinergic activity were associated with an 11% increased odds of dementia. Certain classes of anticholinergic drugs including antidepressants, urological drugs, and antiparkinson drugs showed stronger associations with dementia risk compared to gastrointestinal drugs. The risk of dementia increased with greater exposure and longer duration of use for some drug classes.
Similar to Dementia - what can Public Health do to respond to the scope for Prevention? - Olga Cleary (20)
Loneliness is an important public health issue, especially for older adults. Thomas Prohaska from Ulster University presented on interventions that can help reduce loneliness in later life from December 5-7, 2018. The presentation discussed what types of programs and activities have been shown to effectively help older adults feel less lonely and socially isolated.
This 3 sentence document provides information about a presentation given at an international loneliness symposium in Belfast from December 5-7, 2018. Theo van Tilburg from Vrije Universiteit Amsterdam presented on the topic of older adult's loneliness in the Netherlands. The symposium was hosted by the Institute of Public Health in Ireland and Ulster University's Bamford Centre for Health and Well Being.
Loneliness in the UK is the topic of the document. The author thanks the funders of her work on loneliness and her collaborators for their contributions and tolerance of her obsession with loneliness. The views expressed are the author's own and should not be attributed to others.
Isolation and loneliness are growing problems in the United States, according to experts James Lubben and Louise McMahon Ahearn. Lubben is a professor emeritus at Boston College and co-investigator for the Boston Roybal Center for Active Lifestyle Interventions, while Ahearn is a professor emeritus at both Boston College and UCLA. They have studied isolation and loneliness in older adults in the U.S.
The MESAS approach to evaluating Scotland's alcohol strategy and minimum unit pricing policy focuses on building a robust evidence base through a portfolio of quantitative and qualitative studies. It aims to determine the policy's impact on alcohol consumption and harms while considering external factors, and to communicate findings in a way that informs the upcoming parliamentary vote without becoming too politicized. The evaluation emphasizes theoretical frameworks, mixed methods, transparency, stakeholder engagement, and maintaining its credibility and independence to ensure its findings can guide the future of the policy.
This document discusses the science of human walking and its benefits. It explores how walking first evolved in the sea over 420 million years ago based on genetic studies of sea creatures. While walking was long thought to have originated on land, many bottom-dwelling sea animals actually walk along the ocean floor. The document also examines the cognitive and health benefits of walking, such as increased creativity and reduced dementia risk, and argues that cities and towns should be designed to make walking easy, accessible, safe, and enjoyable for all.
The document summarizes the role of a physiotherapist in promoting physical activity and falls prevention for older adults. It discusses:
- The physiotherapist's work in assessing mobility and falls risk, and providing rehabilitation, education and support.
- Evidence that strength and balance training can improve independence and reduce falls risk.
- Barriers to physical activity for older adults and the importance of multi-agency partnerships to address this.
- Components of effective strength and balance programs and tips for implementation across settings.
The document provides guidelines for promoting physical activity to improve mental and physical health for those with mental illness. It aims to 1) support staff in promoting physical activity as a therapeutic tool and 2) provide strategies for staff to help service users incorporate physical activity. Examples of successful physical activity programs are provided, as are key messages and resources. Participant feedback underscores the benefits of physical activity in improving mood, confidence, and social engagement for those with mental illness.
1) The document outlines the structure of health and social care in Northern Ireland, including Integrated Care Partnerships which bring together providers to deliver coordinated care.
2) It discusses frailty, including risk factors like falls, incontinence, polypharmacy, and social isolation. Integrated Care Partnerships are working on projects to address frailty like falls prevention programs.
3) Screening tools can help identify frailty and related conditions. Outcomes may include new diagnoses, referrals to services, and medication changes. Patients report improved confidence and mobility from strength and balance programs.
This document discusses cardiac rehabilitation (CR) programs. It provides an overview of CR, including that it is an underutilized treatment for cardiovascular disease. CR aims to improve physical and emotional condition through exercise, education, and behavior modification. Eligible patients include those who have had a heart attack, stents, bypass surgery, heart failure, or stroke. The document outlines the components of a CR program, including exercise training, education sessions, assessments, and a team-based approach. It discusses measuring outcomes like improved physical fitness and reducing risk factors. Finally, it emphasizes the benefits of CR in improving physical function, mental health, and quality of life.
This document summarizes Michael McCorry's PhD research on interventions to reduce sedentary behavior in older adults. It outlines the objectives to systematically review literature on physical activity and behavioral interventions targeting sedentary time in older populations. A search of various databases retrieved over 19,000 records, which were screened according to PRISMA guidelines. 10 studies met the inclusion criteria and were reviewed in detail, finding mostly low quality evidence and small effect sizes of interventions. The conclusions call for improved measurement of sedentary behavior and more developed interventions in early-stage research.
This document discusses physical activity promotion in primary care. It finds that the UK has high rates of physical inactivity compared to other countries. Regular physical activity can significantly reduce the risk of diseases like cardiovascular disease, diabetes, and cancer. However, getting patients more active is challenging for general practitioners due to time constraints, lack of knowledge, and limited local exercise options. The document recommends solutions like educational toolkits, social prescribing programs, and designating practices as health and wellness centers to address these barriers and better promote physical activity.
The document summarizes research estimating the lifetime costs of childhood obesity in Northern Ireland. It finds that the total lifetime financial cost is £2.25 billion (€2.53 billion). This cost could be reduced by 15.7% or £353.2 million with a 5% reduction in childhood BMI. Compared to the Republic of Ireland, lifetime costs per person are higher in Northern Ireland due to differences in healthcare systems and discount rates. The research indicates huge future costs of inaction and significant potential savings from modest reductions in childhood obesity.
This document discusses food marketing to children and outlines some of the key issues and opportunities for policy changes. It notes that food marketing spends millions advertising unhealthy products to children and that exposure to food ads can account for up to 23% of the variance in children's food choices and obesity rates. It also discusses how digital marketing may amplify the effects of television advertising on children. The document argues for stronger regulations and policies to restrict unhealthy food marketing to children, in line with WHO recommendations. It identifies upcoming opportunities for policy changes being considered in the UK and Ireland.
This document summarizes Northern Ireland's approach to tackling childhood obesity. It discusses the health risks and costs of childhood obesity. The keynote speakers will discuss the marketing of food to children, lifetime costs of childhood obesity, and Northern Ireland's obesity policy and strategy. Northern Ireland's "A Fitter Future for All" framework aims to create an environment supporting a healthy lifestyle and diet. It outlines actions to address early childhood, school environments, food production, and empowering healthy choices. Implementation involves various partners leading different outcomes to prevent and reduce obesity.
This document summarizes the health and wellbeing curriculum in Irish primary and post-primary schools. It outlines the 7 areas covered in the primary school curriculum, including Social, Personal and Health Education (SPHE) which focuses on health, hygiene, family structures and care for the environment. Physical Education is required for 1 hour per week. The post-primary curriculum includes wellbeing as a new area of learning and focuses on culture, curriculum, relationships and policy. SPHE is optional in senior cycle, while Physical Education is offered as both a curriculum subject and exam subject. Partnerships have been formed between government departments to promote healthy lifestyle initiatives in and out of schools.
This document outlines the organizational structure and funding of the Active School Flag program. It describes the staff roles and committees that oversee the program. It also details the annual funding received from the Department of Education and Skills between 2015-2018, which has totaled €475,000 and supported two employees, resources, and operating costs. An additional €213,000 grant was received from Healthy Ireland to support program expansion. The budget is administered by the Mayo Education Centre and subject to financial controls and independent auditing.
More from Institute of Public Health in Ireland (20)
Osteoporosis - Definition , Evaluation and Management .pdfJim Jacob Roy
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
Mercurius is named after the roman god mercurius, the god of trade and science. The planet mercurius is named after the same god. Mercurius is sometimes called hydrargyrum, means ‘watery silver’. Its shine and colour are very similar to silver, but mercury is a fluid at room temperatures. The name quick silver is a translation of hydrargyrum, where the word quick describes its tendency to scatter away in all directions.
The droplets have a tendency to conglomerate to one big mass, but on being shaken they fall apart into countless little droplets again. It is used to ignite explosives, like mercury fulminate, the explosive character is one of its general themes.
- Video recording of this lecture in English language: https://youtu.be/Pt1nA32sdHQ
- Video recording of this lecture in Arabic language: https://youtu.be/uFdc9F0rlP0
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
Kosmoderma Academy, a leading institution in the field of dermatology and aesthetics, offers comprehensive courses in cosmetology and trichology. Our specialized courses on PRP (Hair), DR+Growth Factor, GFC, and Qr678 are designed to equip practitioners with advanced skills and knowledge to excel in hair restoration and growth treatments.
5-hydroxytryptamine or 5-HT or Serotonin is a neurotransmitter that serves a range of roles in the human body. It is sometimes referred to as the happy chemical since it promotes overall well-being and happiness.
It is mostly found in the brain, intestines, and blood platelets.
5-HT is utilised to transport messages between nerve cells, is known to be involved in smooth muscle contraction, and adds to overall well-being and pleasure, among other benefits. 5-HT regulates the body's sleep-wake cycles and internal clock by acting as a precursor to melatonin.
It is hypothesised to regulate hunger, emotions, motor, cognitive, and autonomic processes.
Pharmacology of 5-hydroxytryptamine and Antagonist
Dementia - what can Public Health do to respond to the scope for Prevention? - Olga Cleary
1. Dementia –what role
for prevention?
Institute of Public Health
Alzheimer’s Society of Ireland
Olga Cleary PhD
IPH Open Conference 14th October 2014
2. Overview
• Prevalence
• Impact
• Evidence
• Terminology
• Dementia protective and risk factors
• Population attributable risk for
modifiable factors in Ireland
• Population approach to dementia
prevention
• Process – embedding dementia
prevention in research, policy and
practice
Why?
What?
How?
3. Emergence of
Neurodegenerative disorders
Epidemiological transition is underway as a result
of demographic ageing, characterised by an
increase in neurodegenerative disorders which will
gradually come to replace the current burden of
chronic degenerative disorders as the primary
cause of morbidity and mortality in the
21st century!
4. Dementia prevalence estimates
• Worldwide - 44 million living with dementia (ADI, 2013)
• Western Europe - 7 million living with dementia in
2010 (Prince, 2009)
• Ireland – 47,744 living with dementia in 2011 (Cahill, and
Pierce 2013).
• Expected to double every 20 years
• By 2031 (if current assumptions hold) estimated to
be 90,000 people living with dementia in Ireland
5. Impact
Care setting Proportion of people
with dementia
Community 63%
Residential Long-stay Care 34%
Acute Care 2%
Psychiatric Care 1%
All 100%
Connolly et al, 2014
• €40,500 - average cost per person with dementia per annum
• €1.69 billion in 2010
Lowin et al, 2001; Trepel 2012
• At the individual level, the economic burden of dementia ranks higher
than stroke, heart disease and cancer combined - allocated resources
substantially lower than each of these individual disease groups
9. Modelling modifiable dementia risk in Ireland
Methodology
- Lancet Neurology
Barnes and Yaffe (2011) and Norton et al (2014)
Systematic reviews & meta-analyses – potentially modifiable factors associated with
increase in Alzheimer’s Disease and cognitive decline (Daviglus et al 2010; McGuiness et al
2009; Profenno 2010)
7 Factors with most consistent evidence:
• Diabetes Mellitus
• Current smoking
• Depression
• Low educational attainment
• Physical inactivity
• Obesity
• Hypertension
• Poor diet (high sat fat/low veg)
Calculated PAR based on RRs from Cochrane reviews/meta-analyses
- Assuming causal relationship between risk factor and disease, PAR is number of cases of a
disease in a population attributable to the risk factor.
Irish prevalence estimates taken from Cahill and Pierce (2013) applying EuroCoDe
dementia prevalence to 2011 census data
10. Population attributable risk and estimated
number of attributable cases in Ireland 2011.
Risk factors TILDA
weighted
prevalence
%
Relative Risk
95% CI’s
PAR
95% CI’s
Number of attributable cases
in 2011 (47,744)
95% CIs
Low
education
38% 1.59 (1.35-1.86) 18.3% (11.7-24.6) 8,737 (5,586-11,745)
Obesity 34% 1.6 (1.34-1.92) 16.9% (10.4-23.8) 8,069 (4,965-11,363)
High Blood
32% 1.61 (1.16-2.24) 16.5% (4.9-28.7) 7,878 (2,339-13,703)
Pressure
Physical
Inactivity
32% 1.82 (1.19-2.78) 20.8% (5.7-36.3) 9,930 (2,721-17,331)
Smoking 20% 1.59 (1.15-2.2) 10.6% (2.9-19.3) 5,060 (1,385-9,215)
Diabetes 8% 1.46 (1.2-1.77) 3.5% (1.6-5.8) 1,671 (764-2,769)
Depression 5% 1.65 (1.42-1.92) 3.1% (2.1-4.4) 1,480 (1,003-2,101)
COMBINED 62.5% (33.6-81.0) 29,840 (16,042-38,673)
11. Strengths and limitations
• Estimates based on best available evidence
• PAR estimates assume a causal relationship between risk factor
and dementia outcome, however dementia is multi-factorial
and it is not known if removal/reduction of single risk factors
will lower incidence
• Relative risks while robust, are not based on Irish data
• Risk relations are taken at particular ages and it was not
possible to model the dynamic interplay of risk factors over the
lifecycle.
• Have not adjusted for the non-independence of risk factors
• May be other important factors influencing risk not accounted
for in analyses.
• Community dwelling population in TILDA (excludes
institutionalised and dementia diagnosed)
12. Implications of study findings
• Reductions in prevalence of key modifiable risk factors for dementia is
likely to lead to a reduction in the onset and prevalence of dementia at
a population level in Ireland.
• Estimated combined PAR for Ireland (independent) = 62.5%
• Pooled methods, accounting for non-independence of the risk factors
examined, estimated a much more conservative effect (Norton, 2014).
• Estimated combined PAR for Europe (independent) = 52.7%
• Estimated pooled combined PAR for Europe (non-independence) =
30.6%
• True effect in modifying risk factors remains unknown and we require
further studies to fully investigate this, but it is likely to lie in the
magnitude of 30-60% in Ireland.
• This equates to 14,243 – 28,468 people living with dementia at any one
time in Ireland.
• €576,841,500 per annum cost of dementia patients
13. Developing a population health approach to
dementia prevention
• Need to mitigate burden of dementia
• Moving from:
• Treatment and management to prevention
• Clinical concepts to public health
• Individual focus to population health focus (WHO, 2012)
• Research to policy and practice
Older people with better vascular health, who have been more
physically, mentally and socially active, whose diet is lower in saturated
fats and higher in vegetable and fruit consumption, who don’t smoke
and who drink alcohol in moderation are significantly less likely on
average to develop dementia.
14. Development of a public health approach to dementia
prevention that is strategic, evidence-based and
comprehensive
(McDaid and McAvoy, 2012 - National Dementia Strategy submission)
• Potential for public health interventions
• Synergies in prevention
• Embed dementia prevention in policy and practice
• Enhance current DoH and HSE strategies and programmes
• Afford priority to counteracting risk factors for CVD
• Appropriate intervention for CVD risk factors and
preventative health practices in primary care
• Concept of brain health emerging as an important
paradigm on the neuroscience and public health agenda
• Social patterning and early years intervention
15. Thank You!
Contact:
olga.cleary@publichealth.ie
Acknowledgements:
Helen McAvoy and Owen Metcalf (Institute of Public Health)
Margaret Crean, Emer Begley and Grainne McGettrick (Alzheimer’s Society
of Ireland)
TILDA team
Editor's Notes
Irish figures based on best available estimates – applied to CSO figures.
We do not have population prevalence rates
Outcomes for people with dementia are poor, with high mortality, increased risk of admission to long-stay care and increased length of stay in hospital. Excess length of hospital stays are significant drivers of costs.
Cost of dementia study attempted to measure, valuate and apply per unit costs for primary, community and hospital based care as well as costs per resident in long-stay care.
Not a simple exercise and provides best estimated costs. Need for improved resource costs for healthcare and requires further sensitivity analyses.
Bust costs are broadly in line with those found in other studies.
The prevalence estimates and costs highlight that significant decisions need to be made regarding the allocation and efficient use of resources both now and into the future…
Promising news that prevention works – there are factors that both promote and reduce dementia risk
Balancing the treatment/management of dementia with prevention strategies – knowing who to target and knowing when to target them..
Issues of inequality in dementia – it is socially patterned
Leading scientists have backed calls for a fresh policy approach to combat dementia in the UK by focusing on reducing risk factors and promoting brain health throughout people’s lives. They said that “a substantial proportion of dementia might be delayed or averted if modifiable risk factors are effectively addressed.”
The UK Health Forum and Public Health England launched a consensus statement on 20 May signed by 59 experts and organisations, including practitioners and researchers in dementia, public health, and non-communicable disease (NCD) prevention. It said that evidence was now “sufficient” to justify action and further research on dementia risk reduction by “reducing the modifiable risk factors and improving the recognised protective factors,” the statement said.
The experts described a “compelling” case for dementia risk reduction to be incorporated into health policies that are designed to tackle NCDs, to make better use of current efforts and resources. …
NICE Guidelines
Systematic Reviews
How we conceptualise dementia prevention is very important – need a framework to operate in – and clear terms and definitions – however to date terms have been ‘confused’ and used interchangeably with poorly defined concepts. Terms tend to develop organically and are applied in the literature without much consideration – leads to a diffuse literature which is unhelpful when examining the evidence base. How each term relates to each other is also unclear – we need more conceptual work on this to provide a clear framework within which to operate in public health.
I use the term ‘Dementia prevention’ to encompass all of these concepts and highlight the importance of the concept of Brain Health which is a positive term useful for health promotion and public health which encapsulates lifecourse influences on cognitive development and maintaining a healthy brain.
Protective factors: High cognitive activity, Health diet, Low to moderate alcohol consumption
Risk factors: Depressed mood, Midlife hypertension, Midlife obesity, Smoking, High cholesterol, Physical inactivity.
Having the following three conditions also places people at higher risk of developing dementia: Diabetes, Chronic Kidney disease and Cardiovascular disease, hence the need for lifestyle changes as part of primary and secondary prevention of these three conditions.
AD is most common cause of dementia 60-80% of all cases.
Delaying symptom onset by 1 year could reduce prevalence by 9 million cases worldwide by 2040.
Calculating population attributable risks
7 risk factors
Number of AD cases that could potentially be prevented
Self reported doctor diagnosis of risk factors in TILDA
Combined estimate is high due to lack of communality analysis on risk factors most recent study applied pooled risk factors to account for the pooled effect of risk factors – concluded that around 30% of cases in the UK are due to the modifiable risk factors accounted for here (independent analysis (before pooling was estimated to be 52%). Likely that the true effect is lower than estimated here.
Estimates based on best available evidence
PAR estimates assume a causal relationship between risk factor and dementia outcome, however dementia is multi-factorial and it is not known if removal/reduction of single risk factors will lower incidence – evidence indicates that increased risk increases incidence – however the corollary has not yet been shown – that decreased risk decreases incidence – research gap.
The need to mitigate the associated burden of dementia moves the onus firmly into the public health arena and there is now an increasing awareness of the need to move the science of dementia prevention into practice. To this end, the World Health Organization has recommended the development of a public health approach to dementia prevention (World Health Organization, 2012) and the Alzheimer’s Association and Centers for Disease Control and Prevention in the U.S. have recently developed a public health road map for dementia prevention (2013) rooted within a population health approach. In its submission to the Department of Health on A National Strategy on Dementia, the IPH advocated for a development of a public health approach to dementia prevention that is strategic, evidence-based, comprehensive and patient-centred (McDaid and McAvoy, 2012).
Older people with better vascular health, who have been more physically, mentally and socially active, whose diet is lower in saturated fats and higher in vegetable and fruit consumption, who don’t smoke and who drink alcohol in moderation are significantly less likely on average to develop dementia. These modifiable risk factors are often conceptualised as delaying factors which postpone the onset of dementia rather than definitively preventing the condition (Gatz et al., 2006). There is now an opportunity to develop and implement strategies to reduce dementia risk in Ireland and reduce the burden of dementia in later life. It is acknowledged that early onset dementia may occur in certain population sub-groups.
Public health interventions potential to reduce prevalence and delay onset
Synergies in prevention
Afford priority to counteracting risk factors for CVD
including diabetes, hypertension, obesity, smoking and physical activity
Enhance current DoH and HSE strategies and programmes
Appropriate intervention for CVD risk factors in primary care
Embedding preventative health practices into primary care services essential to support the prevention of dementia and several chronic conditions in later life.
Concept of brain health emerging as an important paradigm on the neuroscience and public health agenda.
Social patterning and early years intervention